메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Taiwan's CMUH Completes HIMSS "Grand Slam," Achieving DIAM Stage 7 Certification

TAICHUNG, Nov. 18, 2025 -- China Medical University Hospital (CMUH) has secured one of the world's highest honors in digital health, becoming the first hospital in Taiwan to achieve Stage 7 certification under the HIMSS Digital Imaging Adoption Model (DIAM). The designation, awarded by the U.S.-based Healthcare Information and Management Systems Society (HIMSS), represents the pinnacle of excellence in medical imaging worldwide. With this achievement, CMUH has now completed the entire portfolio of HIMSS certifications, earning what hospital Superintendent Dr. Der Yang Cho described as
- 김갑성 기자
- 2025-11-18 09:01
INSTITUTE OF NEURODIVERSITY, NEUROPOWER WORLD, AND SINGAPORE BRINGS NEURODESIGN TO THE FOREFRONT OF SINGAPORE'S URBAN PLANNING

[ 메디채널 김갑성 기자 ] Hazleen Ahmad, Founder of Neuropower World and Chair & Founder of ION Singapore, to launch pilot projects and training programmes embedding neurodesign into workplaces, housing, parks, and transport hubs SINGAPORE, Nov. 18, 2025 -- The Institute of Neurodiversity (ION) Singapore and Neuropower World, dedicated to advancing inclusion and opportunities for neurominorities, hosted their first Neurodesign Roundtable — Re-thinking Urban Spaces: Designing Cities for Every Mind. The session brought together leaders from urban planning, business, and the community to expl
- 김갑성 기자
- 2025-11-18 09:00
MindHYVE's ChironAI™ Showcased at Peshawar Institute of Cardiology's CME on Cardiovascular Imaging Innovation"

PESHAWAR, Pakistan, Nov. 18, 2025 -- The Peshawar Institute of Cardiology – Medical Teaching Institute (PIC-MTI) hosted a high-profile Radiology Continuing Medical Education (CME) session on "Innovations in Cardiovascular Imaging," drawing senior cardiologists, radiologists, and imaging specialists from across Pakistan for an exchange on cutting-edge developments in cardiac imaging and diagnostic technologies. As part of the CME program, Bill Faruki, Founder & CEO of MindHYVE.ai™, was invited to join the event for a live demonstration of ChironAI™ — MindHY
- 김갑성 기자
- 2025-11-18 08:50
Genesis MedTech and National University Health System Forge Strategic Partnership to Advance AI Innovation for Safer, Smarter Surgical Care

SINGAPORE, Nov. 18, 2025 -- Genesis MedTech Group and the National University Health System (NUHS) have formed a strategic partnership to advance artificial intelligence (AI) in surgery and medical device innovation. This partnership stems from a Memorandum of Understanding signed earlier this year, with further details unveiled at the World Congress of Endoscopic Surgery (WCES). As surgical challenges evolve, AI-driven technologies are enabling surgeons with data-driven insights to deliver safer, personalised and better outcomes for patients. At the same time, th
- 김갑성 기자
- 2025-11-18 08:00
European Union and Vietnam: A joint path to poultry farming based on immunity and prevention

HANOI, Vietnam, Nov. 18, 2025 -- To mark the World Antimicrobial Resistance (AMR) Awareness Week, which begins today (18–24 November), the EU co-financed the 'European Poultry – From Our Farms to Your Tables' information and promotional campaign to highlight Vietnam's progress in the rational use of antibiotics in poultry production and the compatibility of European standards with local market expectations. Vietnam accelerates changeIn 2018, the Vietnamese government prohibited the use of antibiotic growth promoters in livestock feed. It also adopted a roadmap to phase out the
- 황정호 기자
- 2025-11-18 07:00
유럽 가금류 업계, 동물에 대한 예방적이고 책임 있는 접근 강조

서울, 대한민국, 2025년 11월 18일 -- 오늘(11월 18~24일) 시작되는 세계 항생제 내성(AMR) 인식 주간(World Antimicrobial Resistance Awareness Week)을 맞아, 유럽연합(EU)은 항생제 내성(AMR) 감소를 위한 유럽 가금류 생산업체의 노력을 조명하기 위해 EU 공동 자금으로 지원되는 '유럽 가금류 – 우리의 농장에서 당신의 식탁까지(European Poultry – From Our Farms to Your Tables)' 정보 및 홍보 캠페인을 진행한다. 유럽연합은 질병으로 인한 치료가 필요한 경우를 제외하고, 동물 생산 과정에서 항생제 사용을 금지하고 있다. 치료가 필요한 경우에도 엄격한 수의학적 감독 아래에서만 이루어지며, 잔류물이 법적 기준 내에 있도록 휴약기간을 철저히 준수한다. EU는 예방과 동물복지를 최우선으로 두고 있으며, '농장에서 식탁까지(Farm to Fork)' 전략에 따라 높은 식품 안전과 전 과정 추적성 수준을 유지하면서 항생제 사용을 더욱 줄이는 것을 목표로 한다. 실제 현장에서 어떻게 운영되는가?유럽의 가금류 생산업체들은 현장에서 엄격한
- 황정호 기자
- 2025-11-18 07:00
Canary Speech Receives Frost & Sullivan's 2025 North America Technology Innovation Leadership Recognition for Technology Innovation Leadership

[ 메디채널 김갑성 기자 ] Recognized for transforming Intelligent Vocal Biomarker Diagnostics through innovative AI-powered, smartphone-based diagnostic solutions SAN ANTONIO, Nov. 17, 2025 -- Frost & Sullivan is pleased to announce that Canary Speech, a global leader in AI-powered vocal biomarker technology, has received the 2025 North America Technology Innovation Leadership recognition in the intelligent vocal biomarker diagnostics industry for its outstanding achievements in technology innovation. This recognition highlights Canary Speech's consistent leadership in driving measurable o
- 김갑성 기자
- 2025-11-17 23:00
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it has been named the winner of the "Best ADC Preclinical Publication 2024" at the 12th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP® linker technology. The honored
- 김갑성 기자
- 2025-11-17 22:26
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

BOSTON, Nov. 17, 2025 -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round. This Series A-2 financing reflects strong participation from Bambusa's existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Inv
- 김갑성 기자
- 2025-11-17 22:15
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic thera
- 김갑성 기자
- 2025-11-17 22:06

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2026-03-03_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 12시 20분